South Korean firm begins prostate cancer trial with J&J drug
In short
- The first patient was dosed Monday in the Phase 1b/2 JET trial, the company said Thursday.
- The trial tests GI-102 with pasritamig in metastatic castration-resistant prostate cancer.
- The trial is global, and the source reports no results yet.
Why it's good news
Metastatic castration-resistant prostate cancer is an advanced form that is hard to treat. The trial has only just begun dosing, so it does not yet show whether the combination works. It is a step toward testing a possible treatment, not a treatment in use.
From The Korea Herald
South Korean biotech firm GI Innovation has administered the first dose in a global clinical trial combining its experimental immunotherapy GI-102 with Johnson & Johnson's prostate cancer drug candidate pasritamig, marking a new step in its efforts to develop treatments for advanced cancer. The company said Thursday that the first patient was dosed Monday in the Phase 1b/2 JET trial, which is evaluating the combination in patients with metastatic castration-resistant prostate cancer, an advanced